| Identification | Back Directory | [Name]
LY 267108 | [CAS]
105882-69-7 | [Synonyms]
LY 267108
NMIWBQUQCOMGHJ-XWVSLMRSSA-N
Erythromycin Ethyl succinate Impurity F
8,9-Anhydropseudo-erythroMycin A-6,9-heMiketal
Erythromycin Impurity 15(Erythromycin EP Impurity F)
Erythromycin Impurit F:(pseudoerythromycin A enol ether)
Erythromycin EP Impurity F/(2R,3R,6R,7S,8S,9R,10R)-3-((2R,3R)-2,3-dihydroxypentan-2-yl)-9-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-7-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-2,6
(2R,3R,6R,7S,8S,9R,10R)-7-[(2,6-Dideoxy-3-C-Methyl-3-O-Methyl-α-L-ribo-hexopyranosyl)oxy]-3-[(1R,2R)-1,2-dihydroxy-1-Methylbutyl]-2,6,8,10,12-pentaMethyl-9-[[3,4,6-trideoxy-3-(diMethylaMino)-β-D-xylo-hexopyranosyl]oxy]-4,13-dioxabicyclo[8.2.1]tridec-12-en-5-one
4,13-Dioxabicyclo[8.2.1]tridec-12-en-5-one, 7-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-3-[(1R,2R)-1,2-dihydroxy-1-methylbutyl]-2,6,8,10,12-pentamethyl-9-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (2R,3R,6R,7S,8S,9R,10R)-
(2R,3R,6R,7S,8S,9R,10R)-7-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy]-3-[(1R,2R)-1,2-dihydroxy-1-methylbutyl]-2,6,8,10,12-pentamethyl-9-[[3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl]oxy]-4,13-dioxabicyclo[8.2.1]tridec-12-en-5-one | [Molecular Formula]
C37H65NO12 | [MDL Number]
MFCD09841212 | [MOL File]
105882-69-7.mol | [Molecular Weight]
715.91 |
| Chemical Properties | Back Directory | [Melting point ]
127.0-130.0 °C | [Boiling point ]
810.7±65.0 °C(Predicted) | [density ]
1.20±0.1 g/cm3(Predicted) | [storage temp. ]
−20°C | [solubility ]
DMF: Soluble; DMSO: Soluble; Ethanol: Soluble; Methanol: Soluble | [form ]
neat | [pka]
13.45±0.70(Predicted) |
| Hazard Information | Back Directory | [Chemical Properties]
White Solid | [Uses]
Erythromycin impurity. | [Uses]
Pseudoerythromycin A enol ether is a degradation product of erythromycin formed by a complex internal rearrangement of erythromycin A on exposure to neutral to weakly alkaline conditions. The C6–OH forms an internal enol ether with the C9 ketone of erythromycin, while the C11-OH attacks the carbonyl of the lactone to reduce the macrocycle from a 14- to an 11-membered macrolide. Synthetically, pseudoerythromycin A enol ether is prepared by reacting erythromycin enol ether with carbonate. Pseudoerythromycin A enol ether is devoid of antibiotic activity but is an important analytical standard for erythromycin A stability studies. | [in vivo]
Pseudoerythromycin A enol ether (LY267108) increases lower esophageal sphincter (LES) pressure in cats[2]. |
|
| Company Name: |
Lynnchem
|
| Tel: |
86-(0)29-85992781 17792393971 |
| Website: |
http://www.lynnchem.com/ |
| Company Name: |
Novachemistry
|
| Tel: |
44-20819178-90 02081917890 |
| Website: |
https://www.novachemistry.com/ |
|